Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG CLASS:

IGF-1R inhibitor

DRUG CLASS:

IGF-1R inhibitor

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Related drugs:

ALK positive	Non Small Cell Lung Cancer	ALK positive	Non Small Cell Lung Cancer	SY-707 Sensitive: C2 – Inclusion Criteria SY-707 Sensitive : C2	SY-707 Sensitive: C2 – Inclusion Criteria SY-707 Sensitive : C2
IGF1R underexpression	Ewing Sarcoma	IGF1R underexpression	Ewing Sarcoma	mTOR inhibitor + IGF-1R inhibitor Sensitive: C3 – Early Trials mTOR inhibitor + IGF-1R inhibitor Sensitive : C3	mTOR inhibitor + IGF-1R inhibitor Sensitive: C3 – Early Trials mTOR inhibitor + IGF-1R inhibitor Sensitive : C3
IGF1 elevation	Ewing Sarcoma	IGF1 elevation	Ewing Sarcoma	CP-751,871 Sensitive: C3 – Early Trials CP-751,871 Sensitive : C3	CP-751,871 Sensitive: C3 – Early Trials CP-751,871 Sensitive : C3
PTPRD R995C	Ewing Sarcoma	PTPRD R995C	Ewing Sarcoma	mTOR inhibitor + IGF-1R inhibitor Sensitive: C3 – Early Trials mTOR inhibitor + IGF-1R inhibitor Sensitive : C3	mTOR inhibitor + IGF-1R inhibitor Sensitive: C3 – Early Trials mTOR inhibitor + IGF-1R inhibitor Sensitive : C3
PTPRD V253I + PTPRD W775stop	Ewing Sarcoma	PTPRD V253I + PTPRD W775stop	Ewing Sarcoma	mTOR inhibitor + IGF-1R inhibitor Sensitive: C3 – Early Trials mTOR inhibitor + IGF-1R inhibitor Sensitive : C3	mTOR inhibitor + IGF-1R inhibitor Sensitive: C3 – Early Trials mTOR inhibitor + IGF-1R inhibitor Sensitive : C3
PTPRD V253I + PTPRD W775stop	Ewing Sarcoma	PTPRD V253I + PTPRD W775stop	Ewing Sarcoma	IGF-1R inhibitor Sensitive: C3 – Early Trials IGF-1R inhibitor Sensitive : C3	IGF-1R inhibitor Sensitive: C3 – Early Trials IGF-1R inhibitor Sensitive : C3
IGF1 elevation	Pancreatic Cancer	IGF1 elevation	Pancreatic Cancer	AMG 479 Sensitive: C3 – Early Trials AMG 479 Sensitive : C3	AMG 479 Sensitive: C3 – Early Trials AMG 479 Sensitive : C3
IGF2 elevation	Pancreatic Cancer	IGF2 elevation	Pancreatic Cancer	AMG 479 Sensitive: C3 – Early Trials AMG 479 Sensitive : C3	AMG 479 Sensitive: C3 – Early Trials AMG 479 Sensitive : C3
IGFBP2-L	Pancreatic Cancer	IGFBP2-L	Pancreatic Cancer	AMG 479 Sensitive: C3 – Early Trials AMG 479 Sensitive : C3	AMG 479 Sensitive: C3 – Early Trials AMG 479 Sensitive : C3
IGFBP3 elevation	Pancreatic Cancer	IGFBP3 elevation	Pancreatic Cancer	AMG 479 Sensitive: C3 – Early Trials AMG 479 Sensitive : C3	AMG 479 Sensitive: C3 – Early Trials AMG 479 Sensitive : C3
HR negative	HER2 Negative Breast Cancer	HR negative	HER2 Negative Breast Cancer	AMG 479 Sensitive: C3 – Early Trials AMG 479 Sensitive : C3	AMG 479 Sensitive: C3 – Early Trials AMG 479 Sensitive : C3
IGFBP5-L	HER2 Negative Breast Cancer	IGFBP5-L	HER2 Negative Breast Cancer	AMG 479 Sensitive: C3 – Early Trials AMG 479 Sensitive : C3	AMG 479 Sensitive: C3 – Early Trials AMG 479 Sensitive : C3